Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast

Annals of Allergy, Asthma and Immunology

Volumn 90, Issue 5, 2003, Pages 536-542

  Ratner, Paul H ^a   Howland III, William C ^b   Arastu, Raiqua ^c   Philpot, Edward E ^d,e   Klein, Kristofer C ^d   Baidoo, Charlotte A ^e   Faris, Melissa A ^d   Rickard, Kathleen A ^d  

^a Sylvana Research Associates   (United States)

^b CEDRA Clinical Research LLC   (United States)

^c Live Oak Allergy and Asthma Clinic   (United States)

^d GLAXOSMITHKLINE   (United States)

^e GLAXOSMITHKLINE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE PROPIONATE; MONTELUKAST; ACETIC ACID DERIVATIVE; ANDROSTANE DERIVATIVE; ANTIALLERGIC AGENT; FLUTICASONE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LORATADINE; QUINOLINE DERIVATIVE;

ADOLESCENT; ADULT; ALLERGIC RHINITIS; AQUEOUS SOLUTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NOSE CONGESTION; OUTCOMES RESEARCH; POPULATION RESEARCH; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SCORING SYSTEM; SNEEZING; SORE THROAT; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; VISUAL ANALOG SCALE; COMPARATIVE STUDY; DRUG EFFECT; HAY FEVER; INTRANASAL DRUG ADMINISTRATION; MULTICENTER STUDY; NOSE OBSTRUCTION; ORAL DRUG ADMINISTRATION;

ACETATES; ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ADULT; ANDROSTADIENES; ANTI-ALLERGIC AGENTS; FEMALE; HUMANS; LEUKOTRIENE ANTAGONISTS; LORATADINE; MALE; NASAL OBSTRUCTION; PRURITUS; QUINOLINES; RHINITIS, ALLERGIC, SEASONAL; SNEEZING;

EID: 0037531122     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61847-9     Document Type: Article

References (18)

1. 1 receptor antagonist in allergic rhinitis: systemic review of randomized controlled trials. BMJ. 1998;317:219-224.
2. Stempel DA, Thomas M. Treatment of allergic rhinitis: an evidenced-based evaluation of nasal corticosteroids versus non-sedating antihistamines. Am J Manag Care. 1998;4:89-96.
3. Meltzer EO, Malmstrom K, Lu S, Prenner BM, Wei LX, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol. 2000;105:917-922.
4. Nayak AS, Philip G, Lu S, Malice MP, Reiss TF. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol. 2002;88:592-600.
5. Philip G, Malmstrom K, Hampel FC, Weinstein SF, LaForce CF, et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy. 2002;32:1020-1028.
6. Pullerits T, Praks L, Baker R, Risioja V, Lotvall J. Comparison of nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol. 2002;109:949-955.
7. Howarth PH. Mediators of nasal blockage in allergic rhinitis. Allergy. 1997;52(Suppl):12-18.
8. 4 on nasal mucosal blood flow, nasal airway resistance, and nasal secretion in humans. Clin Allergy. 1986;60:289-297.
9. 4 in grass pollen-induced rhinitis. Am Rev Respir Dis. 1987;136:357-362.
10. 4 in allergic rhinitis. Ann Allergy. 1988;60:537-540.
11. Dykewicz MS, Fineman S, editors. Diagnosis and management of rhinitis: complete guidelines of the joint task force on practice parameters in allergy, asthma, and immunology. Ann Allergy Asthma Immunol. 1998;81:478-518.
12. Meltzer EO. Nasal cytological changes following pharmacological intervention. Allergy. 1995;50(Suppl):15-20.
13. Meltzer EO. Role of cysteinyl leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis based on the concept of "one linked airway disease." Ann Allergy Asthma Immunol. 2000;84:176-187.
14. O'Byrne PM, Israel E, Drazen JM. Antileukotrienes in the treatment of asthma. Ann Intern Med. 1997;127:472-480.
15. 4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol. 1996;98:528-534.
16. Meltzer EO, Rickard KA, Westlund RE, Cook CK. Onset of therapeutic effect of fluticasone propionate aqueous nasal spray. Ann Allergy Asthma Immunol. 2001;86:286-291.
17. Ratner PH, van Bavel JH, Martin BG, Hampel FC, Howland WC 3rd, et al. A comparison of the efficacy of fluticasone propionate aqueous nasal spray and loratadine alone and in combination, for the treatment of seasonal allergic rhinitis. J Fam Pract. 1998;47:118-125.
18. Berger WB, Shoheiber O, Ledgerwood GL, Cannon E, Giaquinta D. New challenges to old standards in the treatment of rhinitis. Suppl J Manag Care Pharm. 2001;7:2.